Governo sanciona programa para fortalecer setor de fertilizantes
Entrou em vigor, nesta sexta-feira (4/9), o Programa de Desenvolvimento da Indústria de Fertilizantes (Profert), que bus…
Biosurfactant partnerships and facility investments push category toward scale
The personal care industry is directing its attention to biosurfactant innovation as consumers demand gentler and more sustainable solutions. Industry players are investing in the category by launching production facilities to expand global reach and venturing into partnerships to bolster surfactant capabilities.
Fertilizantes: setor prevê queda de até 20% nas entregas
O setor de fertilizantes alerta para o risco de redução nas compras de insumos pelos produtores rurais diante do cenário…
NRAS Mutations May Require Mutation-Guided Combination Therapies
For decades, RAS proteins have occupied a frustrating place in cancer biology: central to tumor growth, yet difficult to drug. Members of the RAS family—KRAS, NRAS, and HRAS—act as molecular switches that help relay growth signals inside cells. When mutated, they can become stuck in a growth-promoting state, driving cancers including melanoma, pancreatic cancers, colorectal cancers, and other malignancies. Although new drug-development efforts have begun to make inroads against KRAS and HRAS, mutant NRAS has remained a particularly challenging target. A new study suggests that one reason is that NRAS-driven cancers may not depend on mutant NRAS alone.
Novartis’ $12B Avidity bet suffers Phase 3 blow
What now: The Swiss drugmaker said it saw signs of clinical activity across secondary and exploratory endpoints and will analyse the full dataset before discussing the programme’s future with regulators.
Core Biogenesis expands longevity concept into eye makeup
Core Biogenesis, a France‑based biotechnology company, is extending its longevity-driven innovation platform to color cosmetics with Eye Longevity Shadow, a formulation concept designed to merge makeup performance with skin care benefits.
Senado aprova projeto de reformulação do seguro rural
O Senado aprovou nesta quinta-feira (3/9) um projeto de lei que reformula o seguro rural, com taxas de juros menores e p…
RS Safra 2025/26: trigo evolui de forma satisfatória
As lavouras de trigo apresentam evolução diferenciada no Rio Grande do Sul, com predominância de áreas em final de desen…
ProBioGen Grants Transgene Additional License for AGE1.CR.pIX Cell Line
ProBioGen and Transgene report that they broadened the scope of their existing collaboration to include an additional license agreement for ProBioGen’s suspension AGE1.CR.plXR cell line which is designed to boost Transgene’s manufacturing capabilities with this specialized production technology.
Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice
The results of a preclinical study by researchers at the University of East Anglia suggest that an experimental anticancer drug could stop osteoporosis and help women prevent weight gain after the menopause. Their study in mice found that the small molecule drug CADD522 not only protected against osteoporosis but could also reduce body fat and reverse some of the metabolic changes linked to menopause. Currently in development for cancer therapy, CADD522 is a small molecule inhibitor of the transcription factor RUNX2, which is helps to drive the growth and spread of several cancers.